---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-030845"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T17:41:15.526376+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences agrees to $40M SEC settlement; ReTHINK Phase 3 top-line due by year end

## Summary
- Agreed to pay $40M civil penalty to SEC for negligent disclosures related to Phase 2b study; DOJ not expected to charge company.
- ReTHINK Phase 3 (804 patients, 77 sites) completed last patient visit; top-line results expected before year end 2024.
- ReFOCUS Phase 3 (1,125 patients) results expected mid-2025; DSMB recommended program continuation without modification.
- Separated CEO and Board Chair roles as part of governance enhancements; Rick Barry remains CEO.
- Nearly 90% of Phase 3 patients elected open-label extension trial; Phase 2 data showed mild patients stable over 24 months on simufilam.

## SEC filing metadata
- accession: 0001437749-24-030845
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/0001437749-24-030845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924030845/sava20241007_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-030845
- JSON: https://secwatch.observer/filing/0001437749-24-030845.json
- Plain text: https://secwatch.observer/filing/0001437749-24-030845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.